#United States #Life Sciences #Zurich #Fapon Biopharma #T-cell Engager

Fapon Biopharma to Introduce Cutting-Edge CD3/TCR VHH TCE Platform

Fapon Biopharma is set to showcase its next-generation T-cell engager (TCE) platform based on CD3/TCR VHH at the 19th Annual European Life Sciences CEO Forum in Zurich. The event, which will be held at the Hilton Zurich Airport from March 4 to 5, 2026, promises to gather key figures from the life sciences industry. Dr. Kaiqing Zhang, Ph.D., the Associate Director of Business/Corporate Development, will present a groundbreaking discussion titled "Unlocking the Next Generation of TCE Platform CD3/TCR VHH with Human/Cynomolgus Cross-Reactivity by Fapon."

The innovative platform developed by Fapon focuses on addressing the complexities associated with traditional multispecific antibodies, utilizing its proprietary TCE based on human/cynomolgus cross-reactive VHH single-domain antibodies. This design fosters a modular, plug-and-play methodology, optimizing activation kinetics and therapeutic index.

The technology underholds tremendous potential in two rapidly advancing therapeutic areas:

Oncology

The TCE platform is tailored for the precise redirection of T cells, aimed at eliminating solid and hematologic tumors. With optimized activation kinetics, the platform ensures an expanded therapeutic index, significantly reducing cytokine release risks.

Autoimmune Diseases

Fapon's solution includes potent T cell activators engineered for the deep depletion of B cells. This unique approach delivers a functional 'immune reset' for patients suffering from refractory diseases, offering new hope in a challenging treatment landscape.

At the core of this technology are unique CD3/TCR VHH constructs exhibiting varying affinities for both human and cynomolgus monkeys. This dual reactivity not only minimizes preclinical safety risks but also accelerates translation timelines. Early evaluation has shown superior efficacy and safety, along with predictable pharmacokinetics across mouse and non-human primate studies.

Fapon Biopharma is actively seeking strategic partners for joint development and licensing opportunities. Interested parties can reach out via their collaboration contact email: [email protected] for inquiries within the United States, Europe, and other regions, or [email protected] for Asia-Pacific inquiries.

About Fapon Biopharma

Fapon Biopharma is dedicated to discovering and developing biological products to combat cancer, autoimmune conditions, and various diseases with unmet medical needs. Harnessing cutting-edge technologies, Fapon has established advanced drug discovery platforms, including a leading antibody discovery platform based on mammalian cell visualization technology, a novel IL-10M fusion protein generation platform, and a cross-species CD3-VHH TCE platform. With a diverse portfolio of innovative drug candidates, Fapon has developed comprehensive capabilities covering the full drug development process, from discovery through preclinical research, chemistry, manufacturing, and controls (CMC) to initial clinical development. Committed to innovation, Fapon aims to provide safer, more effective, and accessible biological products for all patients around the globe.